Clever Culture Systems (CC5) Investor presentation summary

Market context and need

• Environmental monitoring is mandatory in pharmaceutical manufacturing to ensure sterility and patient safety.

• Failures in sterility can lead to catastrophic outcomes, including deaths and product recalls, as seen in the 2023 eye drop contamination case.

• Validated sterility control systems are critical to prevent microbial contamination before products reach patients.

Solution and technology

• APAS Independence uses AI and machine learning to automate microbial quality control, providing faster and more accurate results than manual microbiologist assessments.

• The system offers improved data integrity, automatic audit trails, and easy integration with existing workflows.

• APAS is designed to meet GMP standards, with over 10 years of microbiology expertise embedded in its algorithms.

Business model and revenue

• Each APAS Independence sale can generate up to AU$1.2 million over seven years, combining upfront capital and recurring annual revenue streams.

• Revenue split includes 40% from instrumentation, 40% from software licenses (ARR), 15% from service and maintenance, and 5% from implementation.